Pipeline Data At American Thoracic Society International Conference

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that new Phase 3 data for ARIKAYCE® (amikacin liposome inhalation suspension) in Mycobacterium avium complex (MAC) lung disease will be presented as a late-breaker at the American Thoracic Society (ATS) International Conference, May 17-22, in Dallas. Additional data on ARIKAYCE as well as on Insmed's pipeline candidates will also be presented at the meeting.

Presentations include:

Late-breaker oral session, Monday, May 20, 11:00-11:15 AM CT: A7359 – Sustainability and Durability of Culture Conversion in Patients Receiving Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Mycobacterium avium Complex Lung Disease (MAC-LD) in the CONVERT Study

Oral session, Monday, May 20, 10:15-10:30 AM CT: A2654 – Pharmacokinetic (PK) Evaluation of Amikacin Liposome Inhalation Suspension (ALIS) in Patients with Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease

Oral session, Monday, May 20, 10:00-10:15 AM CT: A2653 – Open-Label Trial of Amikacin Liposome Inhalation Suspension in M. AbscessusLung Disease (Insmed-supported investigator-initiated research)

Poster presentation, Tuesday, May 21, 11:15 AM-1:00 PM CT; A5049 / P1120 – Pain Assessment After Intraplantar Injection of a Remodulin Equivalent Formulation and Subcutaneous Injection of Treprostinil in Rats

Poster presentation, Tuesday, May 21, 11:15 AM-1:00 PM; CT A5055 / P1129 – Determination of the Prostanoid Receptor Subtypes Involved in Treprostinil-Induced Relaxation of Rat Pulmonary Arteries with Intact and Denuded Endothelium

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.